http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Ironwood Pharmaceuticals to Present at 27th Annual Credit Suisse Healthcare Conference
-
Ironwood Pharmaceuticals Provides Third Quarter 2018 Investor Update
-
Ironwood Pharmaceuticals to Host Third Quarter 2018 Investor Update Call
-
Ironwood Pharmaceuticals Presenting IW-3718 and Linaclotide Data at the American College of Gastroenterology 2018 Annual Scientific Meeting
-
Ironwood Pharma (IRWD) Announces FDA Fast Track Designation for Praliciguat for Heart Failure
-
Ironwood Pharmaceuticals Announces FDA Fast Track Designation for Praliciguat for the Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)
-
Ironwood Pharmaceuticals to Present at Upcoming September Investor Conferences
-
Ironwood Pharma (IRWD), Astellas Pharma Inc. Announce Japanese Approval of Linzess Tablets 0.25 mg for Additional Indication of Chronic Constipation
-
Approval of Linzess® Tablets 0.25 mg in Japan for Additional Indication of Chronic Constipation
-
Ironwood Pharmaceuticals Provides Second Quarter 2018 Investor Update
-
Ironwood Pharmaceuticals to Host Second Quarter 2018 Investor Update Call
-
Ironwood Pharma (IRWD) Begins Phase IIIb Study of Linaclotide in Adult Patients with Irritable Bowel Syndrome with Constipation (IBS-C)
-
Ironwood Pharmaceuticals Initiates Phase IIIb Study of Linaclotide in Adult Patients with Irritable Bowel Syndrome with Constipation (IBS-C)
-
Ironwood Pharma (IRWD) Reports Positive Impact from Praliciguat Phase IIa Study Data on Metabolic a& Cardiovascular Clinical Endpoints
-
Ironwood Presents Praliciguat Phase IIa Study Data Showing Positive Impact on Metabolic and Cardiovascular Clinical Endpoints at the American Diabetes Association’s 78th Scientific Sessions
-
Ironwood Pharma (IRWD) Commences Pivotal Phase III Program for IW-3718 in Persistent Gastroesophageal Reflux Disease
-
Ironwood Pharmaceuticals Initiates Pivotal Phase III Program for IW-3718 in Persistent Gastroesophageal Reflux Disease
-
Ironwood Pharmaceuticals to Highlight Clinical and Preclinical Data for Praliciguat at the American Diabetes Association’s 78th Scientific Sessions
-
Ironwood Pharma (IRWD) Announces FDA Orphan Drug Designation for Olinciguat for Treatment of Sickle Cell Disease
-
Ironwood Pharmaceuticals Announces FDA Orphan Drug Designation for Olinciguat for the Treatment of Sickle Cell Disease
-
Ironwood Pharmaceuticals to Present at the Goldman Sachs 39th Annual Global Healthcare Conference
-
Ironwood Pharma (IRWD) Presents IW-3718 Data Showing Improvements in Patients with Persistent GERD at DDW
-
Ironwood Pharmaceuticals Presents IW-3718 Data Showing Improvements in Heartburn and Regurgitation Symptoms in Patients with Persistent GERD at Digestive Disease Week® 2018
-
Ironwood Pharmaceuticals Announces Results of 2018 Annual Meeting of Shareholders
-
Ironwood Pharmaceuticals to Highlight Clinical Data for IW-3718 in Persistent Gastroesophageal Reflux Disease (GERD) at Digestive Disease Week® 2018
-
Ironwood Pharmaceuticals Sends Letter to Shareholders Highlighting Director Nominees
-
Ironwood Pharmaceuticals Files Investor Presentation Highlighting Actions Taken Designed to Unlock Shareholder Value
-
Ironwood Pharma (IRWD) , Allergan (AGN) Announce Settlement with Aurobindo Pharma Resolving LINZESS Patent Litigation
-
Ironwood and Allergan Announce Settlement with Aurobindo Pharma Resolving LINZESS® (linaclotide) Patent Litigation
-
Ironwood Pharmaceuticals Files Definitive Proxy Materials and Mails Letter to Shareholders
-
Allergan and Ironwood Launch Interactive Digital Destination During Irritable Bowel Syndrome (IBS) Awareness Month Designed to Encourage Sufferers to Get Educated and Take Action
-
Ironwood Pharma (IRWD) to Separate Soluble Guanylate Cyclase Business from Commercial and Gastrointestinal Business
-
Ironwood Pharmaceuticals Announces Intent to Separate Soluble Guanylate Cyclase (sGC) Business from Commercial and Gastrointestinal Business
-
Ironwood Pharmaceuticals Provides First Quarter 2018 Investor Update
-
Ironwood Pharmaceuticals to Host First Quarter 2018 Investor Update Call
-
Ironwood Pharma (IRWD) Announces Director Nomination from Sarissa Capital
-
Ironwood Pharmaceuticals Announces Director Nomination from Sarissa Capital
-
Ironwood Pharmaceuticals to Present at Upcoming March Investor Conferences
-
Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2017 Investor Update
-
Ironwood Pharmaceuticals to Host Fourth Quarter and Full-Year 2017 Investor Update Call
-
Ironwood Pharma (IRWD), Allergan (AGN) Settle with Sun Pharma Resolving LINZESS Patent Litigation
-
Ironwood and Allergan Announce Settlement with Sun Pharma Resolving LINZESS® (linaclotide) Patent Litigation
-
Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
-
Ironwood Pharma (IRWD) Commences Phase II Clinical Trial of sGC Stimulator IW-1701 in Patients with Sickle Cell Disease
-
Ironwood Pharmaceuticals Initiates Phase II Clinical Trial of sGC Stimulator IW-1701 in Patients with Sickle Cell Disease
-
Ironwood Pharma (IRWD) Announces Top-Line Phase IIa Data for IW-1973
-
Ironwood Reports Top-line Phase IIa Data for IW-1973 Demonstrating Positive Cardiovascular, Metabolic and Endothelial Effects
-
Ironwood Pharmaceuticals Strengthens Executive Leadership Team
-
Ironwood Pharmaceuticals Provides Third Quarter 2017 Investor Update
-
Ironwood Pharmaceuticals to Present at Credit Suisse 26th Annual Healthcare Conference

